Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EBITDA (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported EBITDA over the past 12 years, most recently at -$120.3 million for Q4 2025.

  • Quarterly results put EBITDA at -$120.3 million for Q4 2025, down 49.1% from a year ago — trailing twelve months through Dec 2025 was -$342.1 million (down 26.58% YoY), and the annual figure for FY2025 was -$342.1 million, down 26.58%.
  • EBITDA for Q4 2025 was -$120.3 million at Viridian Therapeutics, Inc.\DE, down from -$34.3 million in the prior quarter.
  • Over the last five years, EBITDA for VRDN hit a ceiling of -$14.0 million in Q3 2021 and a floor of -$120.3 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$48.4 million (2023), compared with a mean of -$53.0 million.
  • Peak annual rise in EBITDA hit 67.93% in 2021, while the deepest fall reached 179.02% in 2021.
  • Viridian Therapeutics, Inc.\DE's EBITDA stood at -$29.1 million in 2021, then plummeted by 55.45% to -$45.2 million in 2022, then plummeted by 46.92% to -$66.5 million in 2023, then dropped by 21.38% to -$80.7 million in 2024, then plummeted by 49.1% to -$120.3 million in 2025.
  • The last three reported values for EBITDA were -$120.3 million (Q4 2025), -$34.3 million (Q3 2025), and -$100.9 million (Q2 2025) per Business Quant data.